Rocket Pharmaceuticals (RCKT) Form 144 Discloses 699-Share Sale After Vesting
Rhea-AI Filing Summary
Form 144 notice for Rocket Pharmaceuticals, Inc. (RCKT): The filing notifies a proposed sale of 699 common shares through Fidelity Brokerage Services LLC on 08/18/2025, with an aggregate market value of $2,142.57. The shares were acquired by the seller via restricted stock vesting on 08/14/2025 and were issued as compensation. The filing also reports sales by the same person earlier this year: 357 shares sold on 05/20/2025 for $2,301.22 and 7,043 shares sold on 08/14/2025 for $21,260.70. The issuers outstanding shares are listed as 107,903,871.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale following restricted stock vesting; amounts disclosed are small in absolute dollar terms.
The Form 144 documents a proposed sale of 699 common shares acquired via restricted stock vesting on 08/14/2025 and intended to be sold on 08/18/2025 through Fidelity. Two prior sales by the same person earlier in 2025 are disclosed, totaling 7,400 shares. The filing meets Rule 144 disclosure requirements by identifying acquisition dates, nature of acquisition (compensation), broker, and proceeds. From a trading-impact perspective, these transactions appear routine and procedural rather than materially transformative for the issuer.
TL;DR: Disclosure is complete for the transactions shown; this appears to be standard compliance with insider sale rules.
The filer indicates the securities were issued as compensation and vested on 08/14/2025, with planned sale on 08/18/2025. The notice includes prior sales in the past three months, consistent with aggregation requirements. The signer attests they possess no undisclosed material adverse information. This filing documents compliance with Rule 144 and provides transparent traceability of insider dispositions.